SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

Andere talen Shin Nippon Biomedical Laboratories, Ltd.

Aandelen

2395

JP3379950003

Beurs gesloten - Japan Exchange Andere beurzen 08:00:00 02-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1.535 ^JPY	-0,45%		+2,20%	-9,60%

02/02	Shin Nippon Biomedical Laboratories, Ltd. Geeft geconsolideerde winstrichtlijnen voor het jaar dat eindigt op 31 maart 2024	CI
2023	Shin Nippon Biomedical Laboratories, Ltd. Kondigt een interim-dividend aan voor het jaar eindigend op 2024, betaalbaar op 30 november 2023; geeft richtlijnen voor het dividend voor het jaar eindigend op 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024	02/02
Shin Nippon's STS101 Faces Regulatory Hurdle, FDA Requests Refinement for Approval	18/01
Shin Nippon Biomedical Laboratories : 英語版株主通信（2023/04/01~2023/09/30）を発行しました	27/12
Shin Nippon Biomedical Laboratories, Ltd. Announces Interim Dividend for the Year Ending March 31, 2024, Payable on November 30, 2023; Provides Dividend Guidance for the Year Ending March 31, 2024	07/11
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	02-08-23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	02-08-23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be presented at the American Headache Society's 65th Annual Scientific Meeting	16-06-23
Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to be Presented at the American Headache Society’s 65th Annual Scientific Meeting	15-06-23
Satsuma Pharmaceuticals and Shin Nippon Biomedical Laboratories, Ltd. Announce Three Abstracts on STS101 for the Acute Treatment of Migraine to Be Presented at the American Headache Society's 65th Annual Scientific Meeting	15-06-23
Shin Nippon Biomedical Laboratories, Ltd. completed the acquisition of the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers.	08-06-23
Shin Nippon Biomedical Laboratories, Ltd. Reports Earnings Results for the Full Year Ended March 31, 2023	08-05-23
Shin Nippon Biomedical Laboratories, Ltd. Provides Dividend Guidance for Second Quarter and Full Year Ending March 31, 2024	08-05-23
Shin Nippon Biomedical Laboratories, Ltd. Announces Year End Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023	08-05-23
Shin Nippon Biomedical Laboratories, Ltd. Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2023 and Full Year Ending March 31, 2024	08-05-23
Shin Nippon Biomedical to Make $30 Million Offer for US-based Satsuma Pharmaceuticals	18-04-23
Sector Update: Health Care Stocks Higher Premarket Monday	17-04-23
Bank Earnings in Focus as US Equity Futures Tread Water	17-04-23
Top Premarket Gainers	17-04-23
Satsuma Pharmaceuticals to be Acquired by Shin Nippon Biomedical	17-04-23
Shin Nippon Biomedical Laboratories, Ltd. entered into an agreement to acquire the remaining 91.6% stake in Satsuma Pharmaceuticals, Inc. from a group of sellers for $27.6 million.	17-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Shin Nippon Biomedical Laboratories, Ltd.

Aandelen

2395

JP3379950003

Andere talen

Filters